Poor understanding about vaccine capacity was one of the reasons why the world did not have the infrastructure needed to manufacture sufficient doses. This blogs proposes three actions to start tracking manufacturing capacity better and create robust estimates for the world’s vaccine manufacturing capacity.
CGD Policy Blogs
Before Recommending the RTS,S Malaria Vaccine for Wider Use, WHO Should Address Three Key Considerations
Last month, the world woke up to promising news on malaria prevention: administering an existing malaria vaccine (RTS,S) in addition to antimalarial drugs before the rainy season reduced child hospitalizations and deaths by approximately 70 percent in Burkina Faso and Mali. These results arrived ahead of a forthcoming decision from the World Health Organization on whether to recommend RTS,S for broader use. This blog argues that WHO should consider value for money and address three key considerations before making their reccomendation.
LAC Countries are Struggling to Deliver COVID-19 Vaccinations—Six Actions Are Needed to Turn the Tide
Historically, the Americas have been the world leader in routine vaccination, vaccine introduction, and implementation of mass vaccination campaigns against infectious diseases. It was the first region to eliminate rubella and measles, eradicate smallpox, and be declared polio-free.
Vaccines have become a central instrument of our long-term response to the pandemic. Vaccination campaigns have now started around the world and will confer significant direct protection against infection, severe illness, and death to those inoculated. It may also protect against transmission, though robust evidence is yet to be confirmed.
Effective vaccines are developed through collaboration between governments, publicly funded research universities and for-profit pharmaceutical companies. But the incentives to produce the doses can often leave out lower-income countries.
Five key operational levers and choices determine how fast countries are able to roll out the COVID-19 vaccine. Ideally, someone at the national level makes these decisions, but this hasn’t always been easy in multi-level government systems.
At a recent CGD staff presentation of our work into COVID-19 vaccines, our colleagues raised a large number of interesting questions, so, we asked our colleagues to send in their questions on the COVID-19 vaccine portfolio.
As COVID-19 vaccines begin to emerge, policymakers around the world are feeling buoyant. Although governments will be the initial recipients of vaccines, their decisions on how to distribute these among their populations will be fundamental for the ultimate recipients: individuals.
Today we launch an interactive tool that analyses the COVID-19 vaccine portfolio, and generates estimates about the timelines for the vaccines in the portfolio.
Beyond the Rhetoric of Equity: Will the Frontline Healthcare Workers Who Serve the Poor Be Prioritized for the COVID Vaccine?
Healthcare providers, particularly in low- and middle-income countries, are a diverse, fragmented, and loosely regulated population. Will the COVID vaccine plans prioritize them?